Google
GKOS Stock Analysis — GLAUKOS CORP (Healthcare >> Medical Devices)
GKOS FAQ
What is GKOS's ROE?
GLAUKOS CORP reports a Return on Equity (ROE) of -27.55%.
What is GKOS's dividend yield?
GLAUKOS CORP offers a dividend yield of 0.00%.
What is GKOS's Quality Score?
Our AI rates GKOS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GKOS?
Our AI Timing Score for GKOS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GKOS belong to?
GLAUKOS CORP is classified under the Healthcare >> Medical Devices sector on the NYSE exchange
GKOS AI Analysis Summary
Our AI summary for GKOS: GLAUKOS CORP (NYSE), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 0.00, ROE of -27.55%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 166.72
Price
-1.80
(-1.07%)
Day Change
|
|
|---|
GKOS, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 166.72 |
| PBV / Sector |
14.56 / -101.57
|
| Earning Per Share | -3.15 |
| PE / Sector |
N/A / 31.23
|
| PEG or PE/Growth / Sector |
N/A / 0.40
|
| Average 1M Daily Value |
137.66 M
GREAT
|
| Average 1W Daily Value |
278.88 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:54 |
| Symbol | GKOS |
| Name | GLAUKOS CORP |
| Sector | Healthcare >> Medical Devices |
| Market | NYSE |
| Listed Shares | 58.98 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 9,939.97 / 20,104.97 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Glaukos Way, Aliso Viejo, CA, United States, 92656
Phone: 949 367 9600
Website: https://www.glaukos.com
Employees: 1,094
Sector: Healthcare >> Medical Devices
Description: Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
